Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis

Authors

Jonathan Cooper, Cornell University
Qingwen Xu, University of Texas MD Anderson Cancer Center
Lu Zhou
Milica Pavlovic, Memorial Sloan-Kettering Cancer Center
Virginia Ojeda, Memorial Sloan-Kettering Cancer Center
Kamalika Moulick, Memorial Sloan-Kettering Cancer Center
Stanchina E de
John T. Poirier, Memorial Sloan-Kettering Cancer Center
Marjorie Zauderer, Cornell University
Charles M. Rudin, Memorial Sloan-Kettering Cancer Center
Matthias A. Karajannis, Memorial Sloan-Kettering Cancer Center
C. Oliver Hanemann, Peninsula Medical School
Filippo G. Giancotti, University of Texas MD Anderson Cancer Center

ORCID

• C. Oliver Hanemann: 0000-0002-1951-1025

DOI Link

10.1158/1535-7163.MCT-16-0821

Publication Date

2017-05-03

Publication Title

Molecular Cancer Therapeutics

ISSN

1535-7163

Acceptance Date

2017-04-20

Embargo Period

2018-05-03

Recommended Citation

Cooper, J., Xu, Q., Zhou, L., Pavlovic, M., Ojeda, V., Moulick, K., de, S., Poirier, J., Zauderer, M., Rudin, C., Karajannis, M., Hanemann, C., & Giancotti, F. (2017) 'Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis', Molecular Cancer Therapeutics, . Available at: 10.1158/1535-7163.MCT-16-0821